The Chief Drug Officer of India (DCGI) today granted limited use permission to Covaxin Bharat Biotech for children in the age range of 6-12 years amid an increase in Covid cases in schools.
The approval by DCGI was made following the recommendation of the Subject Expert Committee (SEC) on COVID-19 from the Central Drugs Control Organization (CDSCO).
DCGI has instructed vaccine makers to submit safety data, including data on adverse events, with due diligence every 15 days for the first two months. After two months, Bharat Biotech was asked to submit data every month for up to 5 months.
Covaxin was given an Emergency Use Listing by DCGI for the age group of 12 to 18 years on December 24, 2021. It is now given to those in the age group of 15-18
Further, DCGI also grants emergency use permission to Corbevax for children between the ages of 5-12 years. Corbevax is currently given to children in the 12-14 age group.
Covid-19 vaccination for adolescents in the age group of 15-18 years began on January 3 this year. The drive was later expanded to include children 12 years of age and older last month.
India began giving preventive doses of the vaccine to healthcare and front -line workers as well as those aged 60 and above with comorbidities starting January 10. The preventive dose of COVID-19 vaccine to all those aged 18 and over is allowed at private vaccination centers from 10 April.
India launched a vaccination drive for everyone over the age of 45 on April 1 last year. The government then decided to expand its vaccination efforts by allowing all people aged 18 and above to be inoculated against the viral disease from May last year.